摘要
目的探讨EB病毒壳抗原(VCA)、早期抗原(EA)和核抗原潜伏蛋白(EBNA1)免疫球蛋白A抗体(IgA)的检测对鼻咽癌血清学诊断的意义。方法应用免疫酶法(IE)和酶联吸附试验(ELISA)检测326例鼻咽癌患者、1290例非鼻咽癌门诊患者、职工体检767例血清中EB病毒VCA/IgA、EA/IgA、NA1/IgA抗体。结果鼻咽癌患者VCA/IgA、EA/IgA、EBNA1/IgA抗体阳性率分别为97.9%、81.9%、和87.7%;非鼻咽癌患者组为18.0%、0.2%、和15.3%;对照组为5.1%、0、13.8%。鼻咽癌组的三种IgA抗体阳性率均分别高于非鼻咽癌组和对照组(P<0.001),非鼻咽癌组的VCA/IgA抗体阳性率亦高于对照组(P<0.001)。检测VCA/IgA的灵敏度和特异度为97.9%和94.9%;EA/IgA为81.9%和100%;EBNA1/IgA为87.7%和86.2%。结论 VCA灵敏度和特异度都在较高的水平;EA灵敏度低特异度高;EBNA1灵敏度和特异度不及VCA,提示免疫酶法检测VCA/IgA抗体仍然是鼻咽癌血清学诊断中理想的方法,ELISA法EBNA1/IgA检测灵敏度和特异度比前者低有待进一步改进。
Objective To investigate the significance of detections of immunoglobulin （Ig） A antibodies against Epstein - Barr virus （EBV） viral capsid antigen （ VCA）, early antigens （EA） and nuclear antigen - 1 （ EBNAI ） in nasopharyngeal carcinoma （NPC） diagnosis. Methods Serum samples derived from 326 patients with NPC, 1209 non - NPC outpatients and 767 healthy controls were examined for the presence of VCA/IgA and EA/IgA by immunoenzymatic assay （IE）, EBNA1/IgA by enzyme - linked immnunosorbent assay （ ELISA ）. Results The positive rates of VCA/IgA, EA/IgA and EBNA1/IgA in NPC group were 97.9%, 81.9% and 87.7% ; those in non - NPC group were 18.0%, 0. 2% and 15.3% ; and those in control group were 5. 1%, 0 and 13.8%, respectively. The positive rates of all three antibodies in NPC group were significantly higher than those in non - NPC group and control group, respectively （ P 〈0. 001 ）. And the positive rate of VCA/IgA in non - NPC group was also significantly higher than that in control group （P 〈0. 001 ）. The sensitivity and specificity of VCA/IgA were 97.9 % and 94.9%, respectively; those of EA/IgA were 81.9% and 100% ; those of EBNAI/IgA were 87.7% and 86.2%. Conclusion The detection of VCA/IgA had higher sensitivity and specificity. There were low sensitivity and the highest specificity of EA/IgA. And the sensitivity and specificity of EBNA1/IgA was lower than those of VCA/lgA. These results suggest that VCA/IgA detected by IE still play important roles in NPC diagnosis, and EBNA1/IgA detected by ELISA remains to be improved further.
出处
《中国医学创新》
CAS
2009年第27期101-103,共3页
Medical Innovation of China
关键词
鼻咽肿瘤
EB病毒
免疫酶技术
酶联吸附试验
Nasopharyngeal carcinoma
Epstein - Barr virus
Immunoenzymatic assays
Enzyme - linked immnunosorbent assay
